BiotechTube

Tucatinib 150 MG + Trastuzumab + Capecitabine

Phase 2Recruiting
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

HER2-positive Breast Cancer

Conditions

HER2-positive Breast Cancer, LMD

Trial Timeline

Nov 25, 2023 → Oct 5, 2028

NCT ID
NCT06016387

About Tucatinib 150 MG + Trastuzumab + Capecitabine

Tucatinib 150 MG + Trastuzumab + Capecitabine is a phase 2 stage product being developed by Biocon for HER2-positive Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06016387. Target conditions include HER2-positive Breast Cancer, LMD.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06016387Phase 2Recruiting

Competing Products

20 competing products in HER2-positive Breast Cancer

See all competitors
ProductCompanyStageHype Score
ALT-P7 (HM2-MMAE)AlteogenPhase 1
33
CT-0508 + PembrolizumabCarisma TherapeuticsPhase 1
25
CT-0525Carisma TherapeuticsPhase 1
25
TrastuzumabCelltrionPhase 3
77
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
77
YH32367YuhanPhase 1/2
41
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
23
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
23
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
23
Trastuzumab deruxtecan (T-DXd)Daiichi SankyoPre-clinical
23
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecan + Placebo + Taxane + Pertuzumab + TrastuzumabDaiichi SankyoPhase 3
77
DS-8201a + T-DM1Daiichi SankyoPhase 3
77
Pertuzumab + Trastuzumab + eribulinEisaiPhase 2
52
SHR-A1811 Injection + SHR-A1811 Injection ； Pertuzumab Injection + Trastuzumab Injection；Pertuzumab Injection ； Docetaxel InjectionJiangsu Hengrui MedicinePhase 3
77
PyrotinibJiangsu Hengrui MedicinePre-clinical
23
SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3
77
Pyrotinib + Placebo Oral Tablet + Trastuzumab + DocetaxelJiangsu Hengrui MedicinePhase 3
77
SHR-A1811 + Ramucirumab / Paclitaxel/ Docetaxel/ IrinotecanJiangsu Hengrui MedicinePhase 3
77
pyrotinib tablet + Montmorillonite Power + LoperamideJiangsu Hengrui MedicinePhase 1
33

Other Products from Biocon

Stelara + Bmab1200Phase 3
77
EQ001 + EQ001 PlaceboPhase 3
77
Itolizumab + EQ001 PlaceboPhase 3
77
Humira 40 MG in Prefilled Syringe + Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled SyringePhase 3
77
Bmab 1000 + Prolia®Phase 3
77